Revolution Medicines
Stock Forecast, Prediction & Price Target
Revolution Medicines (RVMD) stock Price Target by analysts
$65.8
Potential upside: 80.07%
Revolution Medicines price prediction
What is Revolution Medicines stock analysts` prediction?
Revolution Medicines stock forecast: Based on 4 Wall Street analysts` predicted price targets for Revolution Medicines in the last 3 months, the avarage price target is $65.8, with a high forecast of $NaN. The average price target represents a 80.07% change from the last price of $36.54.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Revolution Medicines stock Price Target by analysts
Full breakdown of analysts given Revolution Medicines price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joseph Catanzaro Piper Sandler | 0% 0/2 | 11 months ago | $70 91.57% upside | $56.09 | StreetInsider | Previous targets (1) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/1 | 11 months ago | $62 69.67% upside | $55.87 | StreetInsider | Previous targets (0) |
Michael Schmidt Guggenheim | 0% 0/1 | 11 months ago | $82 124.41% upside | $46.96 | TheFly | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/3 | 11 months ago | $60 64.20% upside | $46.83 | StreetInsider | Previous targets (2) |
Jay Olson Oppenheimer | 0% 0/3 | 12 months ago | $55 50.51% upside | $49.22 | StreetInsider | Previous targets (2) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | about 1 year ago | $57 55.99% upside | $44.24 | StreetInsider | Previous targets (1) |
Ami Fadia Needham | 0% 0/2 | about 1 year ago | $61 66.94% upside | $42.73 | StreetInsider | Previous targets (1) |
Robert Driscoll Wedbush | 0% 0/1 | about 1 year ago | $59 61.46% upside | $47.01 | TheFly | Previous targets (0) |
Ben Burnett Stifel Nicolaus | 0% 0/1 | over 1 year ago | $43 17.67% upside | $35.83 | StreetInsider | Previous targets (0) |
Ami Fadia Needham | 0% 0/2 | over 1 year ago | $46 25.88% upside | $37.41 | StreetInsider | Previous targets (1) |
Jay Olson Oppenheimer | 0% 0/3 | over 1 year ago | $45 23.15% upside | $37.41 | StreetInsider | Previous targets (2) |
Laura Prendergast Raymond James | 0% 0/1 | over 1 year ago | $48 31.36% upside | $32.99 | StreetInsider | Previous targets (0) |
Dane Leone Raymond James | 100% 1/1 | almost 2 years ago | $30 -17.89% downside | $21.25 | Benzinga | Previous targets (0) |
Unknown Needham | N/A | almost 3 years ago | $31 -15.16% downside | $23.68 | Benzinga | N/A |
Revolution Medicines Financial Estimates
Revolution Medicines Revenue Estimates
Revolution Medicines EBITDA Estimates
Revolution Medicines Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $29.39M N/A | $35.38M 20.38% | $11.58M -67.26% | Avg: $4.30M Low: $3.69M High: $4.92M avg. -62.79% | Avg: $24.24M Low: $20.77M High: $27.70M avg. 462.62% | Avg: $163.35M Low: $140.01M High: $186.68M avg. 573.85% | Avg: $499.39M Low: $428.05M High: $570.73M avg. 205.71% |
Net Income
% change YoY
| $-179.77M N/A | $-248.70M -38.34% | $-436.36M -75.45% | Avg: $-584.29M Low: $-448.07M High: $-340.58M avg. -33.90% | Avg: $-624.23M Low: $-509.17M High: $-254.58M avg. -6.83% | Avg: $-251.40M Low: $-298.09M High: $-204.71M avg. 59.72% | Avg: $-62.63M Low: $-74.27M High: $-51.00M avg. 75.08% |
EBITDA
% change YoY
| $-187.07M N/A | $-249.12M -33.16% | $-430.58M -72.83% | Avg: $-4.28M Low: $-4.89M High: $-3.67M avg. 99.00% | Avg: $-24.10M Low: $-27.54M High: $-20.65M avg. -462.62% | Avg: $-162.40M Low: $-185.60M High: $-139.20M avg. -573.85% | Avg: $-496.49M Low: $-567.42M High: $-425.56M avg. -205.71% |
EPS
% change YoY
| -$2.47 N/A | -$3.08 -24.69% | -$3.86 -25.32% | Avg: -$3.53 Low: -$3.96 High: -$3.01 avg. 8.61% | Avg: -$3.61 Low: -$4.5 High: -$2.25 avg. -2.45% | Avg: -$2.22 Low: -$2.63 High: -$1.81 avg. 38.51% | Avg: -$0.55 Low: -$0.66 High: -$0.45 avg. 75.08% |
Operating Expenses
% change YoY
| $217.39M N/A | $293.65M 35.07% | $498.76M 69.84% | Avg: $7.91M Low: $6.78M High: $9.04M avg. -98.41% | Avg: $44.52M Low: $38.16M High: $50.88M avg. 462.62% | Avg: $300.03M Low: $257.17M High: $342.89M avg. 573.85% | Avg: $917.25M Low: $786.21M High: $1.04B avg. 205.71% |
FAQ
What is Revolution Medicines stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 23.51% in 2025-2028.
We have gathered data from 11 analysts. Their low estimate is -448.07M, average is -584.29M and high is -340.58M.
What is Revolution Medicines stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 294.85% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $3.69M, average is $4.30M and high is $4.92M.
What is Revolution Medicines stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 29.94% in 2025-2028.
We have gathered data from 11 analysts. Their low earnings per share estimate is -$3.96, average is -$3.53 and high is $-3.01.
What is the best performing analyst?
In the last twelve months 4 analysts have been covering Revolution Medicines stock. The most successful analyst is Joseph Catanzaro.